Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's in Long-Term Care--Treatment for Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No age limit~* probable/possible Alzheimer's disease diagnosis~* disruptive agitated behaviors (e.g., irritability, aggression, uncooperativeness, pacing)~* no hypotension~* no concurrent use of alpha-1-blockers~* no delirium, schizophrenia, mania, psychotic symptoms.~Exclusion Criteria:~* Cardiovascular: unstable angina, recent myocardial infarction, second or third degree atrioventricular (AV) block, preexisting hypotension (systolic blood pressure less than 110) or orthostatic hypotension~* Other medical exclusions: chronic renal or hepatic failure, or any unstable medical condition~* Exclusionary medications: current treatment with prazosin, other alpha-1-blockers~* Current enrollment in a separate investigational drug trial~* Psychoactive medications: subjects may be psychoactive medication-free or be partial responders (by subjective assessment of referring health care professional) to one psychoactive medication from any of the following classes: antipsychotics, anticonvulsants, mood stabilizers, antidepressants, benzodiazepines, or buspirone. Partial response is defined as some improvement in agitated behavior but persistence of agitated behaviors severe enough to cause patient distress and/or difficulty with caregiving. Although not formally rated, this improvement is equivalent to a Clinical Global Impression of Change (CGIC) rating of no more than minimal improvement (improvement is noticed by not enough to improve patient function or caregiver's practical management of the patient).~* Psychiatric/behavioral: lifetime schizophrenia; current delirium, mania, depression, or uncontrolled persistent distressing psychotic symptoms (hallucinations, delusions), substance abuse, panic disorder, or any behavior which poses an immediate danger to patient or others or which results in the patient being too uncooperative to meet the requirements of study participation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prazosin (Type: ACTIVE_COMPARATOR): None
- placebo (inert substance) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).